#106609
Re: Farmas USA
SGYP
Dentro a 1,92
Y persiguiendo ACAD, HZNP, CELG,KERX...
«Después de nada, o después de todo/ supe que todo no era más que nada.»
Se está hablando de:
#106610
Re: Farmas USA
ACAD la estaba mirando yo tambien ...
velas 1h
no me termina de decidir el MACD 2h que se ha ido a bearish ...
#106611
Re: Farmas USA
Celg
Dentro 87,81
Mlnt 10,60
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#106612
Re: Farmas USA
Y ACAD: 24,42
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#106613
Re: Farmas USA
ARNA halted
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#106614
Re: Farmas USA
GLYC
Offering 4,5mill de acc.
A ver mañana a qué precio, puede ser buena entrada
#106615
Re: Farmas USA
ARNA
On March 19, 2018, we announced positive topline Phase 2 results from the OASIS trial for etrasimod, an investigational, once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC). Patients receiving a 2 mg dose of etrasimod achieved statistically significant improvements versus placebo in the primary, all secondary, and clinical remission endpoints.
Relative to placebo, there was a statistically significant (p = 0.009) 0.99 point improvement in a 3-component (stool frequency, rectal bleeding and findings on endoscopy) Mayo Clinic Score (ranging from 0 to 9) with etrasimod 2 mg at week 12. In the 1 mg group, there was a 0.43 point improvement in 3-component Mayo Clinic Score at week 12 relative to placebo, which was not statistically significant (p = 0.146). Significantly more patients in the etrasimod 2 mg group achieved endoscopic improvement compared with placebo (41.8% vs. 17.8%, p = 0.003).
The proportion of patients achieving clinical remission, defined by the 3-component Mayo Clinic Score, was 33.0% in the etrasimod 2 mg group compared to 8.1% for the placebo group (p < 0.001). Remission as defined by the 4-component Total Mayo Clinic Score was 24.5% and 6.0% for etrasimod 2 mg and placebo, respectively (p = 0.004).
Etrasimod was well tolerated and there were fewer patients with serious adverse events (SAEs) compared to placebo (0% in 2 mg, 5.8% in 1 mg and 11.1% in placebo). Impact on heart rate and atrioventricular (AV) conduction was low throughout the study with no discontinuations from study related to bradycardia or AV block. There were no increases in liver function tests compared to placebo and no reports of macular edema or pulmonary function test abnormalities. We plan to present full study results at future medical congresses. We intend to initiate a Phase 3 program for etrasimod in ulcerative colitis.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
#106616
Re: Farmas USA
ARNA
Tela! +60% se han visto